Esperovax was founded in 2018 to advance the development of its Egress RD™ oral vaccine platform, a transformative technology for delivering vaccines to the abundant population of immune cells in the gastrointestinal tract via a small oral capsule. The company's proprietary platform is designed to enable a broad suite of oral vaccines that will be safe, elicit robust immunity, remain stable at room temperature, and can be pr...
Esperovax was founded in 2018 to advance the development of its Egress RD™ oral vaccine platform, a transformative technology for delivering vaccines to the abundant population of immune cells in the gastrointestinal tract via a small oral capsule. The company's proprietary platform is designed to enable a broad suite of oral vaccines that will be safe, elicit robust immunity, remain stable at room temperature, and can be produced at a markedly lower cost than traditional vaccines.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.